Corbus Pharmaceuticals Holdings, Inc. CRBP
2.44 USD -0.31 (-11.29%)
Regular-session close
2.44 0.00 0.00%
After hours · Nov 19, 4:25 PM ET
2.42 Day range 2.88
2.44 52-week range 12.15
- YTD
- -70.09%
- 1 year
- -79.40%
News
defenseworld.net Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Stock Has Average Target Price of $35.67 According to Analysts Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven ratings firms that are covering the stock, MarketBeat.com…
marketbeat.com Corbus Pharmaceuticals Starts Phase 3 Cancer Study, Weighs Next Steps for Obesity Drug Corbus Pharmaceuticals NASDAQ: CRBP has begun a Phase 3 study of its lead cancer drug in second-line oropharyngeal cancer and is considering further development of an obesity treatment that recently…
benzinga.com Biotech ETFs Brace for FDA Showdown: Two Drug Decisions Could Test Investor Sentiment XBI and IBB lagged SPY and QQQ as two FDA decisions and fresh Alzheimer's and obesity-drug data put biotech ETFs in focus.
globenewswire.com Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek® 2026 CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateauing observed Corresponding significant reductions were also seen…benzinga.com Mizuho Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $23 Mizuho analyst Graig Suvannavejh maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $24 to $23.
benzinga.com RBC Capital Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $33 RBC Capital analyst Brian Abrahams maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $36 to $33.
benzinga.com Wedbush Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $27 Wedbush analyst Robert Driscoll maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $30 to $27.
benzinga.com Corbus Pharmaceuticals Q3 EPS $(1.81) Misses $(1.20) Estimate Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.81) per share which missed the analyst consensus estimate of $(1.20) by 50.83 percent. This is a 4.74 percent increase over…
globenewswire.com Corbus Pharmaceuticals Reports Q3 2026 Financial Results and Provides a Corporate Update Dosed first patient in TEMPO-1 registrational study of sutantatug envedotin (CRB-701) in patients with 2L+ oropharyngeal cancer Reported topline data from the CANYON-1 Phase 1b obesity study of…
marketbeat.com Corbus Pharmaceuticals Launches Phase 3 Cancer Trial, Teases More Obesity Drug Data Corbus Pharmaceuticals NASDAQ: CRBP has started a Phase 3 study of its cancer drug CRB-701 and expects an exploratory readout from a separate frontline combination study in the first quarter of next…
globenewswire.com Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in November NORWOOD, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen,…
defenseworld.net Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Stock Now Rated “Moderate Buy” by Wall Street Analysts Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eight analysts that are presently covering the company,…benzinga.com Corbus Pharmaceuticals To Present Late Breaking Data From CRB-913 Canyon-1 Phase 1B Study At Obesity Week 2026 Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that late breaking data from the CRB-913 Canyon-1 Phase…
globenewswire.com Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026 NORWOOD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that…
globenewswire.com Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer Incidence and prevalence of OPSCC continue to rise in the U.S. largely driven by HPV infection OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L+ setting in the U.S. with…
zacks.com Is CRBP a Good Cannabis Investment After Positive Obesity Study Data? Corbus Pharmaceuticals' positive obesity data boosts its cannabinoid strategy, while CRB-701 and cash needs add key context for investors.
marketbeat.com Corbus CRB-913 Delivers 5% Weight Loss in Phase 1b Obesity Study Corbus Pharmaceuticals NASDAQ: CRBP reported top-line results from CANYON-1, a Phase 1b trial evaluating CRB-913, an oral, peripherally restricted CB1 inverse agonist for obesity. The 12-week,…
benzinga.com Corbus Pharmaceuticals Obesity Drug Avoids 'Depressive Effects' Clinical-stage biopharmaceutical firm Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) on Monday reported topline results from its CANYON-1 Phase 1b trial evaluating CRB-913 as an obesity…
globenewswire.com Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateau observed CRB-913 was generally well tolerated with psychiatric…
globenewswire.com Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity Virtual Webcast to be Held Monday, September 14, 2026, at 8:00 AM EDT Virtual Webcast to be Held Monday, September 14, 2026, at 8:00 AM EDT
globenewswire.com Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NORWOOD, Mass., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced the…
globenewswire.com Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity Dose-finding Phase 1b study (n=240) on track for topline data in September 2026 CANYON-1 follows promising data from Phase 1a SAD/MAD study that demonstrated differentiated GI tolerability from GLP-1…
globenewswire.com Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer Company expects to initiate enrollment in TEMPO-1 in September 2026 OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L setting in the U.S. with approximately 14,000…
globenewswire.com Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer NORWOOD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on developing promising new…
marketbeat.com Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near Corbus Pharmaceuticals NASDAQ: CRBP Chief Executive Yuval Cohen outlined the company's near-term clinical readout schedule and development plans for its two lead drug candidates during a Jefferies…
seekingalpha.com Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Key Insights from HNSCC KOL Event Transcript Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Key Insights from HNSCC KOL Event Transcript
